PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29272095-4	2018	DM1-loaded HA-XPS (HA-XPS-DM1) presented a small size of ~80 nm, low drug leakage under physiological conditions, and fast glutathione-triggered drug release.	Glutathione	123-134	immunoglobulin heavy diversity 1-7	Homo sapiens	0-3	
29272095-4	2018	DM1-loaded HA-XPS (HA-XPS-DM1) presented a small size of ~80 nm, low drug leakage under physiological conditions, and fast glutathione-triggered drug release.	Glutathione	123-134	immunoglobulin heavy diversity 1-7	Homo sapiens	26-29	
27723970-2	2016	Here, glutathione-activatable hyaluronic acid-SS-mertansine prodrug (HA-SS-DM1) was designed and developed to achieve enhanced tolerability and targeted therapy of CD44+ human breast tumor xenografts.	Glutathione	6-17	immunoglobulin heavy diversity 1-7	Homo sapiens	75-78	
27723970-8	2016	Glutathione-cleavable HA-SS-DM1 prodrug with superior drug content, excellent targetability, enhanced tolerability, and easy large-scale synthesis appears to be a highly promising alternative to clinically used Trastuzumab emtansine (T-DM1) for targeted breast tumor therapy.	Glutathione	0-11	immunoglobulin heavy diversity 1-7	Homo sapiens	28-31	
27723970-8	2016	Glutathione-cleavable HA-SS-DM1 prodrug with superior drug content, excellent targetability, enhanced tolerability, and easy large-scale synthesis appears to be a highly promising alternative to clinically used Trastuzumab emtansine (T-DM1) for targeted breast tumor therapy.	Glutathione	0-11	immunoglobulin heavy diversity 1-7	Homo sapiens	236-239	
26031461-9	2015	An analysis of bile samples revealed a small fraction of intact DM1 and a predominance of DM1 metabolites formed through oxidation, hydrolysis, S-methylation, and glutathione and its related conjugates.	Glutathione	163-174	immunoglobulin heavy diversity 1-7	Homo sapiens	90-93